Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

417.50DKK
22 Aug 2017
Change (% chg)

kr.12.00 (+2.96%)
Prev Close
kr.405.50
Open
kr.407.00
Day's High
kr.417.50
Day's Low
kr.407.00
Volume
291,945
Avg. Vol
171,642
52-wk High
kr.420.50
52-wk Low
kr.212.50

Latest Key Developments (Source: Significant Developments)

Bavarian Nordic announces price for shares to be issued to Johnson & Johnson Innovation
Wednesday, 9 Aug 2017 02:24pm EDT 

Aug 9 (Reuters) - Bavarian Nordic A/S ::Bavarian Nordic A/S says subscription price is dkk 405.1578 per share of dkk 10.Bavarian Nordic A/S says jjdc will subscribe for Bavarian Nordic shares for $33 million, corresponding to dkk 207 million.  Full Article

Bavarian Nordic: positive data from Phase 2 study of a universal RSV vaccine
Tuesday, 27 Jun 2017 07:59am EDT 

June 27 (Reuters) - BAVARIAN NORDIC A/S :REG-BAVARIAN NORDIC ANNOUNCES POSITIVE DATA FROM ONGOING PHASE 2 STUDY INVESTIGATING A UNIVERSAL RSV VACCINE.SAYS ‍RESULTS CONFIRM INDUCTION OF ANTIBODIES (IGA) ASSOCIATED WITH MUCOSAL RESPONSES​.‍SAYS VACCINE WAS SHOWN TO BE BOTH WELL TOLERATED AND IMMUNOGENIC AT BOTH DOSE LEVELS INVESTIGATED.​.  Full Article

Bavarian Nordic appoints Dr. Tommi Kainu as Chief Business Officer, effective july 1
Wednesday, 10 May 2017 02:59am EDT 

May 10 (Reuters) - BAVARIAN NORDIC A/S :APPOINTS DR. TOMMI KAINU AS CHIEF BUSINESS OFFICER, EFFECTIVE JULY 1.  Full Article

Bavarian nordic Q1 EBIT loss narrows to DKK 3.1 million
Thursday, 4 May 2017 01:38am EDT 

May 4 (Reuters) - Bavarian Nordic A/S ::Q1 EBIT LOSS 3.1 DKK MILLION VERSUS LOSS DKK 152.7 MILLION YEAR AGO.Q1 REVENUE DKK 198 MILLION VERSUS DKK 23 MILLION YEAR AGO.MAINTAINS ITS FINANCIAL EXPECTATIONS FOR 2017.  Full Article

Valneva signs new EB66 commercial license with Bavarian Nordic
Tuesday, 18 Apr 2017 01:01am EDT 

April 18 (Reuters) - Valneva SE ::Announces signing of a new EB66 commercial license with Bavarian Nordic <<>>.Valneva's EB66 cell-line licensed to Bavarian Nordic for MVA-BN based product candidates.Valneva to support process development.The agreement grants Bavarian Nordic the rights to develop and commercialize multiple poxvirus-based vaccines on the EB66 cell-line.  Full Article

Bavarian Nordic FY EBIT rises to DKK 33.0 million
Wednesday, 15 Mar 2017 02:48am EDT 

Bavarian Nordic A/S : FY revenue 1.01 billion Danish crowns ($145 million) versus 1.02 billion crowns year ago . FY EBIT 33.0 million crowns versus 1.6 million crowns year ago . In 2017 sees revenue of 1.30 billion crowns .In 2017 sees EBIT of 350 million crowns.  Full Article

Bavarian Nordic: collaboration to evaluate CV301 and Tecentriq in bladder cancer
Friday, 10 Mar 2017 03:54am EST 

Bavarian Nordic A/S : Announces collaboration to evaluate CV301 and tecentriq in bladder cancer . Agreement with F. Hoffmann-La Roche Ltd (Roche) whereby Roche has agreed to supply their PD-L1 blocking antibody Tecentriq (atezolizumab) for a clinical study combining Bavarian Nordic's cancer vaccine, CV301, and Tecentriq in patients with urothelial carcinoma, or bladder cancer . Roche has committed to supplying Tecentriq to Bavarian Nordic during the phase 2 trial . Bavarian Nordic will be responsible for conducting clinical trial, and both companies will share data from trial .Bavarian Nordic continues to retain all commercial rights to CV301.  Full Article

Bavarian Nordic ups forecast for 2016 year-end cash preparedness
Tuesday, 3 Jan 2017 05:28am EST 

Bavarian Nordic A/S : Upgrades expectations for 2016 year-end cash preparedness to about 2.30 billion Danish crowns ($322.22 million) from about 1.90 billion crowns . Upgrade is primarily result of payments for IMVAMUNE deliveries, which were received earlier than expected and to minor extent increased USD exchange rate as well as deferred investments .Maintains its expectations for 2016 revenues of about 1.00 billion crowns and break-even result before interest and tax.  Full Article

Bavarian Nordic names Christopher Heery Chief Medical Officer
Wednesday, 28 Sep 2016 07:00am EDT 

Bavarian Nordic A/S : Appoints Christopher Heery, M.D., as Chief Medical Officer .Most recently, Dr. Heery was Director of Clinical Trials Group of Laboratory of Tumor Immunology and Biology at National Cancer Institute.  Full Article

Bavarian Nordic Q2 EBIT swings to loss DKK 54.0 million
Wednesday, 17 Aug 2016 01:53am EDT 

Bavarian Nordic A/S : H1 revenue 139 million Danish crowns ($21 million) versus 624 million crowns year ago . Q2 revenue 116.6 million crowns versus 389.1 million crowns year ago . Q2 EBIT loss 54.0 million crowns versus profit 125.0 million crowns year ago .Maintains its financial expectations for 2016.  Full Article

UPDATE 1-Bavarian expands J&J deal to HIV and hepatitis B vaccines, shares jump

July 27 Danish biotech company Bavarian Nordic has expanded its collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson, to also grant the U.S. drugmaker the exclusive rights to its MVA-BN technology for vaccine programmes targeting hepatitis B and HIV-1.